retatrutide dosing schedule clinical trial Schedule: Proven 2026 Guide Retatrutide Dosing Guide for Researchers

November 21, 2019

Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, distinguishing it from semaglutide and tirzepatide

The pill form could also help mitigate one of the recurring challenges with GLP-1s: people regaining weight if they stop taking it

Absolute contraindications Medullary thyroid cancer MEN-2 Pregnancy or breastfeeding Prior severe allergic reaction to GLP-1 medications Conditions requiring extra caution Gastroparesis or delayed gastric emptying History of pancreatitis Advanced diabetic retinopathy Use alongside medications that increase hypoglycemia risk These and a few other situations require individualized assessment, which is why specialty endocrine care matters

Managing adverse effects of incretin-based medications for obesity

GLP-1 is an abbreviation for Glucagon-Like Peptide-1 receptor agonist, which is a class of medications commonly used to treat diabetes and to assist with weight loss in patients with or without diabetes